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Abstract
Current inverse treatment planning methods that optimize both catheter po-
sitions and dwell times in prostate HDR brachytherapy use surrogate linear or
quadratic objective functions that have no direct interpretation in terms of dose-
volume histogram (DVH) criteria, do not result in an optimum or have long solution
times.
We decrease the solution time of existing linear and quadratic dose-based pro-
gramming models (LP and QP, respectively) to allow optimizing over potential
catheter positions using mixed integer programming. An additional average speed-
up of 75% can be obtained by stopping the solver at an early stage, without de-
terioration of the plan quality. For a fixed catheter configuration, the dwell time
optimization model LP solves to optimality in less than 15 seconds, which confirms
earlier results. We propose an iterative procedure for QP that allows to prescribe
the target dose as an interval, while retaining independence between the solution
time and the number of dose calculation points. This iterative procedure is compa-
rable in speed to the LP model, and produces better plans than the non-iterative
QP.
We formulate a new dose-volume based model that maximizes V100% while satis-
fying pre-set DVH-criteria. This model optimizes both catheter positions and dwell
times within a few minutes depending on prostate volume and number of catheters,
optimizes dwell times within 35 seconds, and gives better DVH statistics than dose-
based models. The solutions suggest that the correlation between objective value
and clinical plan quality is weak in existing dose-based models.
This is an author-created, un-copyedited version of an article published in Physics in Medicine and
Biology DOI:10.1088/0031-9155/58/4/1041.
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1 Introduction
1.1 HDR brachytherapy optimization
Interstitial high-dose-rate (HDR) brachytherapy is a form of internal radiation therapy
where a high activity iridium-192 stepping source is temporarily placed into the tumour
volume or its proximity through the use of implanted catheters. This type of radiotherapy
has shown to be an excellent option for the definitive treatment of localized prostate
cancer in any risk category (Yamada et al., 2012). Clinical outcome data shows high
tumour control and low toxicity rates because of the precision and control with which
highly conformal optimized HDR treatment can be delivered.
Treatment planning is one of the steps in the process to deliver the prescribed dose,
and entails two design problems. Firstly, the number and spatial configuration of the
catheters to be implanted has to be determined. Secondly, the spatio-temporal source
stepping pattern within the implanted catheters needs to be calculated. The number and
configuration of catheters depend on the prostate shape, volume, and regional anatomy.
Often a template is used for the transperineal implantation of needles. As each catheter
offers a range of potential stopping points (dwell positions) where the source can stay
for a predefined time (dwell time), the design problem has many degrees of freedom.
Hence, the problem formulation to design an HDR brachytherapy plan comes down to:
1) determine where to insert the catheters in the template, and 2) determine where and
for how long to stop the source inside the catheters to achieve adequate coverage of the
planning target volume (PTV) while sufficiently limiting dose to surrounding organs at
risk (OAR).
Computerized techniques for anatomy-based inverse treatment planning of HDR bra-
chytherapy enable solving these problems by calculating catheter configurations and
source dwell time distributions, based on mathematical optimization models. These mod-
els require the above problem formulation to be translated into a mathematical framework
that describes how the dose distribution depends on the decision variables. Furthermore,
it is mandatory to establish several levels of abstraction to assess the dosimetric quality
of the resulting treatment plan. In this paper, we discriminate between three levels of
abstraction. At the highest level, a dose penalty function is used to assign a penalty
measure to a treatment plan. At the intermediate level, dose-volume-histogram (DVH)
statistics are used to evaluate the dose and dose-volume characteristics of a given dose
distribution. At the lowest level, the opinion of a human expert forms a subjective judge-
ment of the three dimensional dose distribution. Ideally, lower values at the highest level
correspond to better plans when evaluated at the lowest level. We briefly discuss these
three levels, as they are relevant for the remainder of this paper.
Dose penalty functions. As it is impossible to calculate dose deposited to every single
cell, the most relevant tissue volumes (i.e., prostate, urethra, rectum) are discretized into
finite sets of dose calculation points that each represents an adequately small subvolume
where the dose is considered to be uniform. At each point i, the delivered dose, di, is
compared with a prescribed lower bound Li and upper bound Ui. If the delivered dose
is not between these bounds, the violation is penalized. We use the linear and quadratic
penalty function to develop our linear and quadratic dose-based optimization models,
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respectively (Figure 1). For a linear penalty function, costs of αi or βi are incurred per
unit dose (Gy) violation of the lower or upper bound, respectively, whereas for a quadratic
penalty function a dose violation is penalized to the second degree. The total penalty per
tissue structure is the summed penalty over all calculation points within the structure.
The linear penalty function has been used in two well-known algorithms for anatomy-
based inverse treatment planning: Inverse Planning by Simulated Annealing (IPSA)
(Lessard and Pouliot, 2001; Alterovitz et al., 2006) and Hybrid Inverse treatment Plan-
ning and Optimization (HIPO) (Karabis et al., 2005). The quadratic penalty function
has also been discussed in the literature (Milickovic et al., 2002; Lahanas et al., 2003a;
Lahanas and Baltas, 2003).
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Figure 1: The penalty in calculation point i for not satisfying the lower or upper bound
is either linear (a) or quadratic (b) in the violation.
DVH statistics. A typical example of clinically relevant dose-volume criteria for an
HDR brachytherapy prostate plan with 2 fractions of 8.5 Gy following external beam
radiation treatment with 13 fractions of 2.75 Gy is listed in Table 1. The criterion
D90% ≥ 90% requires the hottest 90% of the PTV to receive at least 90% of the prescribed
dose, and V150% ≤ 55% requires the relative volume that is exposed to more than 150%
of the prescribed dose to be less than 55%. For the urethra, D0.1cc ≤ 10 Gy means that
the minimum dose delivered to the hottest 0.1 cc does not exceed 10 Gy.
Table 1: Local protocol based on (Hoskin et al., 2007) of DVH criteria for a prescribed
dose of 8.5 Gy per fraction.
PTV Rectum Urethra
D90% ≥ 90% D10% ≤ 7.2 Gy D10% ≤ 10 Gy
V100% ≥ 90% D2cc ≤ 6.7 Gy D0.1cc ≤ 10 Gy
V150% ≤ 55% V94% = 0 cc V125% = 0 cc
V200% ≤ 20%
Expert opinion. Clinically established DVH criteria are often used as quality indi-
cators of a treatment plan. Computer optimized treatment plans often do not satisfy
pre-set DVH criteria, and hence require a posteriori adjustment of the dwell time dis-
tributions. This is often accomplished using so-called ‘graphical optimization’, see e.g.
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(Morton et al., 2008), or manual adaptation of individual dwell times. The quality of an
optimization method can therefore also be expressed by the time spent to post-process
the plan. It is obvious that the perceived plan quality strongly depends on the level of
experience of the treatment planner.
Mixed integer programming. There is a matured field of research that deals with
optimization problems where (some of the) variables have to be integer, which are inher-
ently difficult to solve to optimality. When applied to problems in which variables are
restricted to 0 or 1, the method starts by solving a relaxed problem where the binary
variables are allowed to take any value between 0 and 1. If in the optimal solution there
is at least one binary variable which is not integer, the method procedes by either (1)
adding a constraint that does not exclude the optimal binary solution, but excludes the
current optimal solution, or (2) splitting the problem into two subproblems, one with
a selected binary variable fixed to 0 and one with the same binary variable fixed to 1.
These steps may be combined, and are repeated until the optimal solution is found. This
way, the method can report an upper and a lower bound on the objective value, where
one corresponds to the current best solution and the other to the solution of a relaxed
problem. We refer the interested reader to (Nemhauser and Wolsey, 1999).
1.2 Our contributions
Currently, only HIPO can solve the problem of catheter placement for prostate HDR
brachytherapy. However, because HIPO is partially based on heuristical optimization,
mathematical optimality of the solution cannot be guaranteed. This means that there
may be solutions with lower objective values, that better satisfy the prescribed dose. We
apply modifications to existing dose-based optimization models, so that a state-of-the-
art mixed-integer linear programming (MILP) or mixed-integer quadratic programming
(MIQP) solver can solve them to optimality.
Conventional quadratic dose-based optimization models have the advantage that the
complexity of the optimization problem is independent of the number of dose calculation
points if the target dose is specified as a single value rather than the interval [Li, Ui]
(Lahanas et al., 2003a; Lahanas and Baltas, 2003). This implies that underdosage and
overdosage are penalized equally, even though the latter is allowed up to Ui. It is our
second contribution to present an iterative procedure for quadratic penalty functions that
retains the advantage of the conventional quadratic dose-based models.
As a third contribution, we present a new model that maximizes PTV coverage while
constraining DVH parameters on the OAR(s). This model has a more direct clinical
interpretation than linear penalty functions, solves in clinically acceptable time and is
expected to produce better treatment plans than dose-based models. Using this model,
we show that dose-based objective functions are bad surrogates for dose-volume based
plan evaluation criteria.
The structure of this paper is as follows. We start by introducing the mathematical
notations and optimization models in Section 2. Our methods are numerically evaluated
on three clinical sample cases in Section 3. The relation to other work is discussed in
Section 4.
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2 Methods
2.1 Mathematical notation
We use the sets, parameters and variables listed in Tables 2-4. The dose delivered to
calculation point i is a linear function of dwell time and dose rate:
(D˙t)i =
∑
j∈J
d˙ijtj. (1)
Table 2: Sets used for inverse treatment planning.
set description
S Tissue structures {PTV, R(ectum), (U)rethra}
Is Calculation points in structure s ∈ S
I All calculation points, IPTV ∪ IR ∪ IU
K Catheters
Jk Dwell positions in catheter k ∈ K
J All dwell positions,
⋃
k∈K Jk
Γ(j) Dwell positions adjacent to dwell position j ∈ Jk within catheter k
Table 3: Parameters used for inverse treatment planning.
parameter unit description
N 1 Upper bound on the number of catheters allowed
tmax s An upper bound on the dwell time for a single dwell position
˙dij Gy The dose rate delivered to calculation point i ∈ I by a source
at dwell position j ∈ J per unit of time
D˙ Gy The first order dose kernel matrix, i.e. the matrix with ele-
ments ˙dij
Li Gy Prescribed lower bound on the dose for calculation point
i ∈ I
Ui Gy Prescribed upper bound on the dose for calculation point
i ∈ I
pi Gy Prescribed dose for calculation point i ∈ I (in case Li = Ui)
p Gy The prescribed dose vector with elements pi
τs 1 Percentage of calculation points receiving a dose less than
Li in structure s ∈ S
αi Gy
−1 Penalty per Gy below the lower bound Li for calculation
point i ∈ I
βi Gy
−1 Penalty per Gy exceeding the upper bound Ui for calculation
point i ∈ I
γ % The maximum allowable relative difference in dwell times
between two adjacent dwell positions
wi 1 Relative weight of calculation point i, wi = 1/|Is| where s is
the structure containing i
W 1 Weight matrix, with wi on the diagonal and 0 at other po-
sitions
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Table 4: Variables used for inverse treatment planning.
variable unit description
tj s Dwell time at dwell position j ∈ J
t s The dwell time vector with elements tj , j ∈ J
vi 1 Binary variable indicating whether calculation point i re-
ceives at most (or at least) its prescribed dose
bk 1 Binary variable indicating whether catheter position k ∈ K
in the treatment template is used
xi 1 Penalty for calculation point i ∈ I
2.2 Optimization models
2.2.1 Linear Dose-based (LD) model.
Using the notation introduced in Section 2.1, the linear dose-based objective function in
Figure 1a can be written as:
min
∑
i∈I max{0, αi(Li −
∑
j∈J d˙ijtj), βi(
∑
j∈J d˙ijtj − Ui)}. (2)
In order to transform this objective function into a model with a linear objective function
and linear constraints, we introduce a variable xi replacing the argument of the max
operator in (2). Additional constraints limit the number of catheters used and the relative
difference in dwell time between adjacent positions. The latter implements the dwell time
modulation restriction (DTMR), that is often used to prevent hot spots (Baltas et al.,
2009). The full model then becomes:
(LD) min
∑
i∈I wixi (3a)
s.t. xi ≥ αi[Li −
∑
j∈J d˙ijtj] ∀i ∈ I (3b)
xi ≥ βi[
∑
j∈J d˙ijtj − Ui] ∀i ∈ I (3c)
tj ≤ bktmax ∀k ∈ K ∀j ∈ Jk (3d)
tj1 ≤ (1 + 100γ)tj2 ∀j1 ∈ J ∀j2 ∈ Γ(j1) (3e)∑
k∈K bk ≤ N (3f)
bk ∈ {0, 1} ∀k ∈ K (3g)
xi ≥ 0 ∀i ∈ I (3h)
tj ≥ 0 ∀j ∈ J. (3i)
The penalty function for calculation point i is a convex piecewise linear function in
the dose
∑
j∈J d˙ijtj. Constraints (3b), (3c) and (3h) together with objective (3a) make
xi equal to the pointwise maximum. If catheter k is not used then bk = 0. Constraint
(3d) sets the dwell times within that catheter to 0 seconds. Constraints (3e) and (3f)
implement the DMTR and enforce no more than N catheters to be selected, respectively.
If the DTMR would be dropped, the model is equivalent to the one described by
Karabis et al. (2009). If additionally the values of bk are fixed, i.e., if all catheter positions
are fixed, the model corresponds to the one by Alterovitz et al. (2006).
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When we solve it as an MILP, the solution times are very high and clinically unac-
ceptable. This is in line with the results from Karabis et al. (2009), where a similar model
could not be solved in less than 5 hours when the number of catheter positions was more
than 25–30.
We have improved the solution time by making two improvements. The first is to
specify constraint (3d) as an indicator constraint, which is an option offered by our solver
that helps treating this constraint more efficiently. Only if bk = 0, the constraint tj = 0
becomes visible to the solver. The second improvement is to make two adjacent catheter
positions mutually exclusive by adding an exclusion restriction bk1 + bk2 ≤ 1 for any two
catheters k1 and k2 that are adjacent in the template. The rationale for this is that two
adjacent catheters are likely to cause high-dose subregions to become connected and form
undesirable hot spots.
2.2.2 Quadratic Dose-based (QD) model.
As an alternative to the (LD) model, we propose a convex quadratic model. If we use a
quadratic objective function, the number of calculation points no longer plays a role, thus
greatly reduces complexity. By using identity (1), (D˙t)i it is evident that
∑
i(wi(Dt)i −
pi)
2 measures the deviation from the prescribed dose pi in calculation point i. This can
also be written as the squared 2-norm ||W(D˙t − p)||22, which is convex in t. Consider
the following constrained least-squares approximation model:
(QD) min ||W(D˙t− p)||22 (4a)
s.t. tj ≤ bktmax ∀k ∈ K ∀j ∈ Jk (4b)
tj1 ≤ (1 + 100γ)tj2 ∀j1 ∈ J ∀j2 ∈ Γ(j1) (4c)∑
k∈K bk ≤ N (4d)
bk ∈ {0, 1} ∀k ∈ K (4e)
tj ≥ 0. (4f)
The objective can be rewritten as: (W(D˙t− p))>(W(D˙t− p)) = t>D˙
>
W
>
WD˙t−
2p
>
W
>
WD˙t + p
>
W
>
Wp. Instead of the full |I| × |J | matrix D˙ it suffices to specify
the |J | × |J | matrix D˙
>
W
>
WD˙ and the |J | × |1| vector D˙
>
W
>
Wp, whose sizes do
not increase with the number of calculation points. The latter has been observed before
by Lahanas et al. (2003a), but has not been used for formulating a convex quadratic
programming model. Instead, these authors formulate nonconvex models, for which op-
timality cannot be guaranteed. However, the (QD) model can be solved to optimality.
The solution time is greatly reduced by adding the exclusion restriction.
In this model, the prescribed dose pi for calculation point i has to be specified. It
is not immediately clear which value should be taken. For points outside the PTV, a
value of 0 is reasonable. For points inside the PTV it is difficult not to penalize very
reasonable values. Finding a good value for pi only gives a target value that is good for
the average calculation point. All calculation points will still contribute some amount
to the objective function even though they receive a dose between Li and Ui. We can
alleviate this disadvantage by solving the problem iteratively. The algorithm starts by
initializing each pi at (Li + Ui) /2. For each iteration, first the problem is solved, then
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pi gets adjusted to a value in [Li, Ui] closest to the dose received in the current optimal
solution. The algorithm stops when the improvement in objective value is sufficiently
small. A very precise description is given in Algorithm B in B. This procedure in general
does not necessarily converge to the global optimum that could have been obtained by
minimizing simultaneously over t, d˙ij and bk, which is proven with a small example in C.
2.2.3 Linear Dose-Volume based (LDV) model.
We propose a new model that maximizes the fraction of the PTV receiving the prescribed
dose, while constraining DVH parameters for OARs. For the rectum and urethra we
enforce D10% ≤ 7.2 Gy and D10% ≤ 10 Gy, respectively. In accordance with Table 1, we
do not allow a dose higher than 8 Gy in the rectum, and 10.6 Gy in the urethra. This
formulation has the advantage that a feasible solution exists (e.g. take all dwell times
equal to 0), and that the solution shows the best target coverage that satisfies clinically
derived DVH constraints. We formulate the model as:
(LDV ) max 1|IPTV |
∑
i∈IPTV vi (5a)
s.t.
∑
j∈J d˙ijtj ≥ Livi ∀i ∈ IPTV (5b)∑
j∈J d˙ijtj ≤ Li + (Ui − Li)(1− vi) ∀i ∈ IR ∪ IU (5c)∑
i∈Is vi ≥ τs|Is| ∀s ∈ {R,U} (5d)
tj ≤ bktmax ∀k ∈ K ∀j ∈ Jk (5e)
tj1 ≤ (1 + 100γ)tj2 ∀j1 ∈ J ∀j2 ∈ Γ(j1) (5f)∑
k∈K bk ≤ N (5g)
bk ∈ {0, 1} ∀k ∈ K (5h)
vi ∈ {0, 1} ∀i ∈ I (5i)
tj ≥ 0 ∀j ∈ J. (5j)
Here Li and Ui have a slightly different interpretation than in the dose-based models.
We select Li = 8.5 Gy for the PTV, (Li, Ui) = (7.2, 8) Gy for the rectum, (Li, Ui) =
(10, 10.6) Gy for the urethra and τR = τU = 0.9.
Constraint (5b) allows vi for i ∈ IPTV to be 1 only if the dose exceeds Li. Hence
objective function (5a) maximizes the number of points inside the PTV that receive the
prescribed dose. Constraint (5c) allows vi for i ∈ IR to be 1 only if the dose is less than
7.2 Gy, and never allows a dose higher than 8 Gy. Constraint (5d) then enforces 90% of
the vi to be 1. Similarly, the same constraints enforce that 90% of the urethra receives
a dose less than 10 Gy, and no part in the urethra receives a dose higher than 125%.
Constraints (5e)–(5g) are the same as constraints (3d)–(3f) in the (LD) model.
By fixing the parameters bk, (LDV) becomes a dwell time optimization model. This
enables a comparison with IPSA, which is not able to optimize catheter positions.
One of the advantages of directly optimizing on clinically relevant criteria is the pos-
sibility to extend the model in a clinically interpretable way. Suppose for instance that
the maximum number of catheters is not fixed a priori, but the planner wants to insert
an extra catheter only if it leads to an improvement of V100% of at least 5%. This can be
incorporated into (LDV) by changing the objective to 1/|IPTV |
∑
i∈IPTV vi + 0.05N and
by treating N as a variable rather than as a parameter.
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3 Numerical evaluation
3.1 Patient data
Clinical data from three different patients have been obtained from the treatment plan-
ning system (HDRplus, version 3.0, Eckert & Ziegler BEBIG GmbH, Berlin, Germany).
Characteristics are summarized in Table 5. Approximately 2500 calculation points have
been hexagonally distributed over the PTV, rectum and urethra. The number of poten-
tial catheter positions in the template is 40, 49 and 43 for patient 1, 2 and 3, having a
prostate volume of 50 cc, 75 cc and 81 cc, respectively. According to our clinical protocol,
the PTV had been extended with a 2 mm margin, and dwell positions were activated
with a separation of 3 mm. A transperineal needle template with a hole resolution of
5 mm was used (Martinez Prostate Template, Nucletron BV, Veenendaal, the Nether-
lands). The dose rates have been calculated using the TG-43 formalism with the source
parameters according to (Granero et al., 2006).
Table 5: Characteristics of the patient data.
Number of calculation points
Structure αi Li βi Ui Patient 1 Patient 2 Patient 3
PTV 8 8.5 3 25 1732 1834 1791
Rectum 0 0 10 8 246 234 240
Urethra 0 0 10 10 489 473 495
3.2 Inverse planning simulated annealing (IPSA)
We compare our results with the IPSA implementation in HDRplus, which exploits the
linear penalty function (2) and was configured as follows. The composite objective func-
tion did not include the total dwell time. A maximum weight was used for the DTMR.
The trade-off between speed and quality was set to its default value. After three consec-
utive runs, the plan with the lowest objective value was selected.
3.3 Our optimization models
For the model parameter values we set tmax at 5 seconds for an apparent source activity
of 370 GBq. The DTMR parameter γ was set at 10%, and the maximum allowed number
of catheters N was varied between 15 and 20.
All computing times reported have been obtained with the optimization software
AIMMS 3.10 x64 using ILOG CPLEX 12.1 as solver running on Windows 7 x64 on an
Intel Core i5 660 (3.33 GHz) processor with 8 GB of RAM.
The exclusion restriction reduces the number of allowed catheter configurations with
a factor 103–108, depending on the prostate volume and number of catheters.
The solution time and objective values of all models are listed in Tables 6–8. The
first line is read as follows: for patient 1, the IPSA model, which is optimized for 16
preselected catheters, returns an optimized plan within 0.8 minutes. If the (LD) model,
9
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Figure 2: Convergence of the lower and upper bound during the optimization of the (LD)
model.
(QD) model, Algorithm 1 or the (LDV) model had chosen the same dwell times as IPSA,
they would have given objective values of 0.9280, 189, 1.1229 or 86.1, respectively. The
other columns show the dosimetric plan performance.
3.3.1 Linear dose-based optimization
The solution times for the (LD) model are 5, 364 and 3 minutes for patients 1, 2 and
3, respectively when the allowed number of catheters is 20. The high solution time for
patient 2 is probably due to the large number of feasible catheter configurations. We
have not been able to obtain a solution within 24 hours without the exclusion restriction.
Specifying constraint (3d) as an indicator constraint decreases calculation time by about
10%.
The convergence rate of the lower and upper bound of V100% during the optimization
process is depicted in Figure 2. We observe that most time is spent on obtaining a better
lower bound. If we would terminate the solver when the upper bound is at most twice
the lower bound, we would get a solution four times quicker at the cost of a 5% higher
objective value. A slightly higher objective value does not translate into a significantly
lower plan quality when evaluated at a lower level (Alterovitz et al., 2006; Karabis et al.,
2009). Hence, stopping early will on average not result in clinically worse treatment
plans.
When the catheter positions are fixed, the (LD) model reduces to an LP. CPLEX finds
the optimal solution in 2.4 seconds. This is comparable to the solution time reported for
a similar LP (Alterovitz et al., 2006; Karabis et al., 2009).
3.3.2 Quadratic dose-based optimization
First, we searched for a good value of pi in the PTV. By repeatedly solving the model
for different target doses and evaluating the dose distribution, we found that 21 Gy gave
an acceptable treatment plan for patient 1. We used the same target value for patient 2
and 3.
The (QD) model solved in between 18 seconds and 1.5 minutes for N = 20 catheter
positions. Again, we observed that the solution time decreased with a larger allowed
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number of catheters. Comparing the solution times to those of the (LD) model, we found
that the (QD) model was at least ten times faster.
For the iterative procedure (Algorithm B), we observed a drop in objective value to
5% of the initial value after the first iteration. In the subsequent 15 steps, the additional
decrement was 40–50%. After 14–24 iterations in total, the decrements in objective value
were smaller than 10−3, which is when the procedure was halted.
When the catheter positions are fixed, and only the dwell times are to be optimized,
the (QD) model solves in 0.14, 0.9 and 0.9 seconds for patients 1, 2 and 3 respectively,
while Algorithm B solves in 8.5, 13.3, and 11.8 seconds, respectively.
3.3.3 Dose-volume based optimization
The solver requires more than 24 hours to solve the (LDV) model to optimality. This
is not problematic, because during execution the solver reports both V100% of the best
solution found so far, and an upper bound on V100% that gradually gets lower. Hence, in
a clinical setting, the treatment planner can stop the solver as soon as the value of V100%
is satisfactory. Here, we stopped as soon as V100% ≥ 95% or after 15 minutes. Stopping
the solver before optimality is reached is not a novel idea. It has been applied before with
low-dose-rate brachytherapy (Gallagher and Lee, 1997; Lee and Zaider, 2003). For dwell
time optimization, the solution time is 8.5 minutes for patient 2. By changing solver
parameters, we have reduced the solution time for dwell time optimization to 14, 30 and
35 seconds for patients 1, 2 and 3, respectively. The new parameters make the solver
first consider solutions in which binary variables that are close to 0 in the LP relaxation,
are fixed at 0. At least 90% of the binary variables must be 1. After fixing 10% of those
variables to 0, the other variables must take the value 1 in the LP relaxation (Pryor and
Chinneck, 2011). We have also tried Benders’ decomposition (Benders, 1962), but it did
not provide a speed-up.
3.4 Plan performance evaluation
All models generate plans with good OAR sparing. The DVH bounds on the rectum and
the urethra are (almost) satisfied in all cases. The V100% for the PTV is sufficiently high
for all models except the (QD) model. V150% and V200% are sufficiently low for all models,
except for the (QD) model.
The plan performance as assessed from the three-dimensional (3D) dose distribution
by an experienced planner (ALH) is listed in the last column of Tables 6-8. The ex-
perienced planner paid most attention to conformality of the dose distribution and to
whether high dose subvolumes (150% and 200%) around dwell positions were connected.
Indeed a high correlation was found between the plan performance scored by the expert
and the COIN value.
The (QD) model produces inacceptable plans due to a low V100%, especially for pa-
tient 2. All other models perform very well, the (LDV) model for patient 1 being an
exception. The latter is due to the activation of dwell positions outside the PTV, giv-
ing rise to significant dose contributions outside the PTV. This can probably be avoided
by activating dwell positions only inside the PTV or by adding constraints on auxiliary
avoidance structures that limit dose outside the PTV.
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The relation between the linear penalty function value and the expert opinion is very
weak. This becomes clear from the objective values of the solution of the (LDV) model:
for patient 3 with 18 catheters the plan of the (LDV) model is still preferred by the expert
even though the linear objective value is 4.6 times higher (0.1038 vs. 0.4816) than the
optimal plan of the (LD) model. Also the relation between the linear objective value and
DVH statistics is weak. For patient 1 with 16 catheters, the plans of the (LD) and (LDV)
models have similar DVH statistics, but their linear penalty value differs by a factor 12
(0.1338 vs. 1.6512).
The effect on the clinical evaluation criteria of extra catheters above 15 is small for all
three patients. In most cases, the models could slightly improve V100% by increasing the
number of catheters, the largest improvement being 2.1%. The expert opinion is almost
constant for a specific patient and model, with most variability related to patient 3. For
this patient, the expert opinion always becomes more positive when more catheters were
inserted.
4 Discussion
With existing dose-based models for inverse treatment planning of HDR brachytherapy,
it is often a trial-and-error process to obtain adequate treatment plans that satisfy pre-set
DVH criteria. In a clinical setting, this is undesirable because of the time burden and
the required degree of user experience. Often, the aim is to design a plan with maximum
achievable target coverage under fixed OAR dose-volume constraints. This type of opti-
mization problem can be formulated and solved using mixed integer programming. This
improves comprehensibility and plan quality compared to traditional dose-based inverse
optimization. We investigated enhancements of existing linear and quadratic program-
ming models for dose-based optimization and showed that the solution time could be
decreased substantially.
We have limited our analysis to three representative clinical cases that cover a range
of prostate sizes. The limited number of patients has allowed us to perform an extensive
analysis of the effects of different algorithms on the allowed number of catheters. We
realize that it is necessary to include more patients to further strengthen our conclusions.
In this dosimetric study, perturbations unavoidable in a clinical implementation were
not taken into account. There is still a lack of validated data on the uncertainties, which
makes it hard to assess the impact of these uncertainties on the optimality of a treatment
plan. In future work the uncertainties need to be identified and quantified, and the effect
on treatment plans needs to be evaluated. Current optimization techniques that deal
with uncertainties such as “stochastic programming” or “robust optimization” require a
model that finds good treatment plans when there is no uncertainty (Ben-Tal et al., 2009;
Kall and Wallace, 1994). This means that our work is also relevant for a future study on
finding robust treatment plans.
For dwell time optimization, all models except (QD) can produce clinically good plans.
This confirms current practice where the (LD) model is used.
Choosing catheter positions is still a difficult problem. Despite the exclusion restric-
tion, only the (LDV) model produces plans in clinically acceptable time for all patients.
There is one other article that uses an exclusion restriction, allowing a maximum of two
12
catheters in any 2 × 2 square of template holes (Holm, 2011). This is weaker than our
restriction. The HIPO algorithm is widely used and can optimize catheter positions in
clinically acceptable time. HIPO inherently differs from our mixed integer programming
approach, making it difficult to clarify any discrepancies.
DVH-based optimization has been applied to HDR brachytherapy by others (Lahanas
et al., 2003b; Panchal, 2008; Siauw et al., 2011). All restrict to dwell time optimization
and use heuristics for which mathematical optimality cannot be guaranteed. Of these,
only Siauw et al. (2011) provide a fast solution to a MILP formulation, but cannot provide
a good upper bound for V100%.
Weak correlation between the (LD) objective value and DVH parameters was also
observed by Holm (2011). Holm claims that the (LD) objective can make a rough division
between good and bad plans. We confirm that there could be an order of magnitude
difference in (LD) objective values among good plans. This implies there is a gap between
the objective function in dose-based models and clinically desired properties of a dose
distribution. The (LDV) model has the potential to close this gap, and to give the
planner a better tool to steer the optimization.
5 Conclusion
With the proposed extensions, existing dose-based optimization models that simultane-
ously optimize catheter positions and dwell times can be solved more quickly to proven
optimality with mixed integer programming techniques. Our dose-volume based model
relates more closely with clinical parameters compared to dose-based models, and is faster
to solve.
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B Iterative procedure for adjusting the target dose
in the (QD) model
for i ∈ I do
pi := (Li + Ui)/2
end for
CURVAL := ∞
repeat
solve the (QD) model
OLDVAL := CURVAL
CURVAL := (QD).value
for i ∈ I do
if (D˙t)i < Li then
pi := Li
else if (D˙t)i > Ui then
pi := Ui
else
pi := (D˙t)i
end if
end for
until OLDVAL − CURVAL ≤ 
C Counter example for global convergence of the it-
erative procedure
We show that Algorithm B does not always converge to the global optimum that we
would have obtained by optimizing the (QD) model simultaneously over t, p and bk.
Consider two mutually exclusive catheter positions, each offering one dwell position.
There are three calculation points; the first one has (L1, U1) = (8, 10) and the other
two have (L2, U2) = (L3, U3) = (10, 15). All dose rates are 1 except d22 = d23 = 2. In
the first iteration we start with prescribed dose vector p = (9 12.5 12.5), in which case
catheter position 2 is optimal with a dwell time of 118/18 s. The new prescribed dose
vector becomes p = (8 13.1 13.1). In every subsequent iteration, the dose vector gets
closer to (8 15 15), resulting in a total penalty of 2/9. But the optimal dose distribution
is obtained by selecting catheter position 1, which can deliver a dose of 10 Gy to all three
calculation points, resulting in a total penalty of 0.
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